Ignite Creation Date:
2024-10-26 @ 3:37 PM
Last Modification Date:
2024-10-26 @ 3:37 PM
Study NCT ID:
NCT06547736
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-08-07
Brief Title:
Exploratory Platform Research on Precision Therapy of Advanced Pancreatic Cancer
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Single-center Open-label Exploratory Platform Research on Precision Therapy of Advanced Pancreatic Cancer
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The study is being conducted to evaluate the safety tolerability and efficacy of ADC drugs monotherapy or combination therapy with HRS-4642 in subjects with locally advanced or metastatic pancreatic cancer
Detailed Description:
This study is an open single center exploratory clinical trial aimed at evaluating the efficacy and safety of ADC drugs monotherapy or combination therapy with HRS-4642 in the treatment of patients with unresectable locally advanced or metastatic pancreatic cancer
This study experiment is divided into two stages dose exploration stage and efficacy exploration stage During the dose exploration phase RP2D was determined based on the safety tolerability and preliminary efficacy data of ADC drugs monotherapy or combination therapy with HRS-4642 and then entered the efficacy exploration phase
This study experiment is divided into two stages dose exploration stage and efficacy exploration stage During the dose exploration phase RP2D was determined based on the safety tolerability and preliminary efficacy data of ADC drugs monotherapy or combination therapy with HRS-4642 and then entered the efficacy exploration phase
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None